Oppenheimer Asset Management Inc. Aerie Pharmaceuticals Inc Transaction History

Oppenheimer Asset Management Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$12.0 - $16.13 $13,044 - $17,533	-1,087 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$11.84 - $25.52 $1,835 - $3,955	155 Added 16.63%	1,087 $15,000
Q4 2019 Feb 07, 2020	SELL	$17.72 - $25.1 $7,601 - $10,767	-429 Reduced 31.52%	932 $23,000
Q3 2019 Oct 31, 2019	BUY	$18.41 - $28.0 $533 - $812	29 Added 2.18%	1,361 $26,000
Q2 2019 Aug 09, 2019	BUY	$28.97 - $48.21 $9,878 - $16,439	341 Added 34.41%	1,332 $39,000
Q1 2019 Apr 24, 2019	BUY	$36.32 - $49.25 $35,993 - $48,806	991 New	991 $47,000
Q4 2017 Feb 07, 2018	SELL	$50.85 - $65.1 $9,254 - $11,848	-182 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$48.6 - $60.1 $8,845 - $10,938	182	182 $9,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.